Loading
A phase 2 trial of Pegfilgrastim in ovarian cancer, run by TORL Biotherapeutics, LLC, now recruiting.
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. is a phase 2 interventional study registered as NCT06690775 by TORL Biotherapeutics, LLC, with 230 participants planned, started 2024-11-20 and due to reach its primary completion in 2027-10. Interventions recorded: TORL-1-23, TORL-1-23, TORL-1-23, Pegfilgrastim (drug). Conditions listed: Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer. No results are recorded here; the registry entry is the source.
Shares TORL BioTherapeutics, Ovarian cancer.
Shares Pegfilgrastim, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares Growth factors: G-CSF and febrile neutropenia prevention, Pegfilgrastim.